Advertisement

Addressing and Managing Requests to Hasten Death

  • Neal Weisbrod
  • Timothy E. QuillEmail author
Chapter

Abstract

In this chapter we discuss how to respond to and address requests by a patient for a hastened death. The initial response should always be exploration and maximization of palliative care. For persistent requests to hasten death that are rational and not the result of inadequate palliative care, discussion and education about the following options are appropriate: withdrawal/withholding of life-sustaining treatment, palliative sedation, voluntarily stopping eating and drinking (VSED), physician-assisted death (PAD), and voluntary active euthanasia (VAE). This discussion will be colored by the legal status for the latter two options in the jurisdiction in which the conversation is being held. We recommend referral to a palliative medicine specialist if there is any uncertainty about the appropriateness of the intervention, and in all cases where palliative sedation to unconsciousness, VSED, PAD, or VAE are being considered. Neurologic patients may present particular challenges in these circumstances. We use amyotrophic lateral sclerosis (ALS), Parkinson disease, Alzheimer’s disease, Huntington’s disease, stroke, and glioblastoma as model diseases to explore the special circumstances in neurology and how various options for a hastened death may be more or less appropriate depending on the underlying illness.

Keywords

Hastened death Palliative sedation Voluntarily stopping eating and drinking (VSED), or patient refusal of hydration and nutrition (PRHN) Physician assisted death (PAD), or physician aid-in-dying, or physician assisted suicide Voluntary active euthanasia (VAE) Medical ethics Primary palliative care Amyotrophic lateral sclerosis (ALS) Parkinson disease Alzheimer’s disease Dementia Huntington’s disease Glioblastoma Stroke 

References

  1. 1.
    Carver AC, et al. End-of-life care: a survey of US neurologists’ attitudes, behavior, and knowledge. Neurology. 1999;53(2):284–93.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Quill TE, Battin MP. Physician-assisted dying: the case for palliative care and patient choice. Baltimore: Johns Hopkins University Press; 2004. xv, 342 pGoogle Scholar
  3. 3.
    Quill T, Arnold RM. Evaluating requests for hastened death #156. J Palliat Med. 2008;11(8):1151–2.PubMedCrossRefGoogle Scholar
  4. 4.
    Ganzini L, Goy ER, Dobscha SK. Why Oregon patients request assisted death: family members’ views. J Gen Intern Med. 2008;23(2):154–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Meier DE, et al. Characteristics of patients requesting and receiving physician-assisted death. Arch Intern Med. 2003;163(13):1537–42.PubMedCrossRefGoogle Scholar
  6. 6.
    Tolle SW, et al. Characteristics and proportion of dying Oregonians who personally consider physician-assisted suicide. J Clin Ethics. 2004;15(2):111–8.PubMedGoogle Scholar
  7. 7.
    Wang LH, et al. Death with dignity in Washington patients with amyotrophic lateral sclerosis. Neurology. 2016;87(20):2117–22.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Battin MP, et al. Physician-assisted suicide: toward a comprehensive understanding. Report of the Task Force on Physician-assisted Suicide of the Society for Health and Human Values. Acad Med. 1995;70(7):583–90.Google Scholar
  9. 9.
    Foley KM, Hendin H. The case against assisted suicide: for the right to end-of-life care. Baltimore: Johns Hopkins University Press; 2002. xii, 371 pGoogle Scholar
  10. 10.
    Battin MP, et al. Legal physician-assisted dying in Oregon and the Netherlands: evidence concerning the impact on patients in “vulnerable” groups. J Med Ethics. 2007;33(10):591–7.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Emanuel EJ, et al. Attitudes and practices of euthanasia and physician-assisted suicide in the United States, Canada, and Europe. JAMA. 2016;316(1):79–90.PubMedCrossRefGoogle Scholar
  12. 12.
    Quill TE, Kimsma G. End-of-life care in The Netherlands and the United States: a comparison of values, justifications, and practices. Camb Q Healthc Ethics. 1997;6(2):189–204.PubMedCrossRefGoogle Scholar
  13. 13.
    Burkle CM, Schipper AM, Wijdicks EF. Brain death and the courts. Neurology. 2011;76(9):837–41.PubMedCrossRefGoogle Scholar
  14. 14.
    Wijdicks EF, et al. Evidence-based guideline update: determining brain death in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74(23):1911–8.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Quill TE, Abernethy AP. Generalist plus specialist palliative care – creating a more sustainable model. N Engl J Med. 2013;368(13):1173–5.CrossRefGoogle Scholar
  16. 16.
    Holloway R. Patients who never leave us. Neurology. 2011;77(15):3.CrossRefGoogle Scholar
  17. 17.
    Russell JA, Williams MA, Drogan O. Sedation for the imminently dying: survey results from the AAN Ethics Section. Neurology. 2010;74(16):1303–9.PubMedCrossRefGoogle Scholar
  18. 18.
    ten Have H, Welie JV. Palliative sedation versus euthanasia: an ethical assessment. J Pain Symptom Manag. 2014;47(1):123–36.CrossRefGoogle Scholar
  19. 19.
    Pope TM, West A. Legal briefing: voluntarily stopping eating and drinking. J Clin Ethics. 2014;25(1):68–80.PubMedGoogle Scholar
  20. 20.
    Quill TE, Lo B, Brock DW. Palliative options of last resort: a comparison of voluntarily stopping eating and drinking, terminal sedation, physician-assisted suicide, and voluntary active euthanasia. JAMA. 1997;278(23):2099–104.PubMedCrossRefGoogle Scholar
  21. 21.
    Ivanovic N, Buche D, Fringer A. Voluntary stopping of eating and drinking at the end of life – a ‘systematic search and review’ giving insight into an option of hastening death in capacitated adults at the end of life. BMC Palliat Care. 2014;13(1):1.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Bolt EE, et al. Primary care patients hastening death by voluntarily stopping eating and drinking. Ann Fam Med. 2015;13(5):421–8.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Meier DE, et al. A national survey of physician-assisted suicide and euthanasia in the United States. N Engl J Med. 1998;338(17):1193–201.PubMedCrossRefGoogle Scholar
  24. 24.
    Initiative and Referendum Institute. 2017. Cited 8 Feb 2017. Available from: http://www.iandrinstitute.org/index.cfm.
  25. 25.
    Okie S. Physician-assisted suicide – Oregon and beyond. N Engl J Med. 2005;352(16):1627–30.PubMedCrossRefGoogle Scholar
  26. 26.
    Hedberg K, Hopkins D, Kohn M. Five years of legal physician-assisted suicide in Oregon. N Engl J Med. 2003;348(10):961–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Brody H. Kevorkian and assisted death in the United States. BMJ. 1999;318(7189):953–4.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    van der Heide A, et al. End-of-life decision-making in six European countries: descriptive study. Lancet. 2003;362(9381):345–50.PubMedCrossRefGoogle Scholar
  29. 29.
    van der Heide A, et al. End-of-life practices in the Netherlands under the Euthanasia Act. N Engl J Med. 2007;356(19):1957–65.PubMedCrossRefGoogle Scholar
  30. 30.
    Rabkin J, et al. Cognitive impairment, behavioral impairment, depression, and wish to die in an ALS cohort. Neurology. 2016;87(13):1320–28.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Ganzini L, et al. Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide. N Engl J Med. 1998;339(14):967–73.PubMedCrossRefGoogle Scholar
  32. 32.
    Veldink JH, et al. Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands. N Engl J Med. 2002;346(21):1638–44.PubMedCrossRefGoogle Scholar
  33. 33.
    Brookmeyer R, et al. Survival following a diagnosis of Alzheimer disease. Arch Neurol. 2002;59(11):1764–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Roberson ED, et al. Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology. 2005;65(5):719–25.PubMedCrossRefGoogle Scholar
  35. 35.
    de Beaufort ID, van de Vathorst S. Dementia and assisted suicide and euthanasia. J Neurol. 2016;263(7):1463–7.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Henig R.M. The last day of her life. The New York Times Magazine 2015 May 14 2015. Cited 16 October 2016. Available from: http://www.nytimes.com/2015/05/17/magazine/the-last-day-of-her-life.html.
  37. 37.
    Goodarzi Z, et al. Detecting depression in Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;87(4):426–37.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Buter TC, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70(13):1017–22.PubMedCrossRefGoogle Scholar
  39. 39.
    Aarsland D, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387–92.PubMedCrossRefGoogle Scholar
  40. 40.
    Peralta E. As planned, right-to-die advocate brittany maynard ends her life. The Two-Way November 3, 2014. Available from: http://www.npr.org/sections/thetwo-way/2014/11/03/361094919/as-planned-right-to-die-advocate-brittany-maynard-ends-her-life.
  41. 41.
    Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842–50.PubMedCrossRefGoogle Scholar
  42. 42.
    Woehrer A, Bauchet L, Barnholtz-Sloan JS. Glioblastoma survival: has it improved? Evidence from population-based studies. Curr Opin Neurol. 2014;27(6):666–74.PubMedGoogle Scholar
  43. 43.
    Quill TE, Holloway R. Time-limited trials near the end of life. JAMA. 2011;306(13):1483–4.CrossRefGoogle Scholar
  44. 44.
    Paulsen JS, et al. Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2005;17(4):496–502.PubMedCrossRefGoogle Scholar
  45. 45.
    Di Maio L, et al. Onset symptoms in 510 patients with Huntington’s disease. J Med Genet. 1993;30(4):289–92.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Duff K, et al. Psychiatric symptoms in Huntington’s disease before diagnosis: the predict-HD study. Biol Psychiatry. 2007;62(12):1341–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Kirkwood SC, et al. Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol. 2001;58(2):273–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Koennecke HC, et al. Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unit. Neurology. 2011;77(10):965–72.PubMedCrossRefGoogle Scholar
  49. 49.
    Andersen KK, Andersen ZJ, Olsen TS. Predictors of early and late case-fatality in a nationwide Danish study of 26,818 patients with first-ever ischemic stroke. Stroke. 2011;42(10):2806–12.PubMedCrossRefGoogle Scholar
  50. 50.
    Saver JL, Altman H. Relationship between neurologic deficit severity and final functional outcome shifts and strengthens during first hours after onset. Stroke. 2012;43(6):1537–41.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Quill TE. Doctor, I want to die. Will you help me? JAMA. 1993;270(7):870–3.PubMedCrossRefGoogle Scholar
  52. 52.
    Dobscha SK, et al. Oregon physicians’ responses to requests for assisted suicide: a qualitative study. J Palliat Med. 2004;7(3):451–61.PubMedCrossRefGoogle Scholar
  53. 53.
    Emanuel EJ, et al. The practice of euthanasia and physician-assisted suicide in the United States: adherence to proposed safeguards and effects on physicians. JAMA. 1998;280(6):507–13.PubMedCrossRefGoogle Scholar
  54. 54.
    Shanafelt TD, et al. Burnout and satisfaction with work-life balance among US physicians relative to the general US population. Arch Intern Med. 2012;172(18):1377–85.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of Rochester School of MedicineRochesterUSA
  2. 2.Palliative Care Division, Department of MedicineUniversity of Rochester School of MedicineRochesterUSA

Personalised recommendations